UNITED STATES NEWS

FDA panel endorses booster shot for J&J COVID-19 vaccine

Oct 15, 2021, 11:00 AM | Updated: Oct 17, 2021, 10:08 pm
FILE - In this March 3, 2021 file photo, a vial of the Johnson & Johnson COVID-19 vaccine is displa...

FILE - In this March 3, 2021 file photo, a vial of the Johnson & Johnson COVID-19 vaccine is displayed at South Shore University Hospital in Bay Shore, N.Y. U.S. health advisers are meeting Friday, Oct. 15, to tackle who needs boosters of Johnson & Johnson's single-shot COVID-19 vaccine and when. Advisers to the Food and Drug Administration also will examine data suggesting that booster of a competing brand might provide better protection. (AP Photo/Mark Lennihan, File)

(AP Photo/Mark Lennihan, File)

WASHINGTON (AP) — U.S. health advisers endorsed a booster of Johnson & Johnson’s COVID-19 vaccine Friday, citing concern that Americans who got the single-dose shot aren’t as protected as those given two-dose brands.

J&J told the Food and Drug Administration that an extra dose adds important protection as early as two months after initial vaccination — but that it might work better if people wait until six months later. Unable to settle the best timing, the FDA’s advisory panel voted unanimously that the booster should be offered at least two months after people got their earlier shot.

“I think this frankly was always a two-dose vaccine,” said FDA adviser Dr. Paul Offit of Children’s Hospital of Philadelphia. “It would be hard to recommend this as a single-dose vaccine at this point.”

The FDA isn’t bound by the recommendation as it makes a final decision — and adding to the debate’s complexity, new research also suggests that J&J recipients might have a stronger immune response if their booster dose is from a competing brand.

Preliminary results from an ongoing study of different ways to “mix and match” different shots showed that a booster of any sort revved up people’s levels of virus-fighting antibodies — at least for a few weeks. And the most dramatic jump came from giving a Pfizer or Moderna shot after the single-dose J&J vaccination.

FDA’s advisers didn’t vote on whether that should be recommended but told the government to allow flexibility with boosters, saying there were no safety red flags even if it’s not yet clear just how much difference, if any, mixing and matching may make in long-term protection.

“In the real world all these kind of combinations are already happening so I think it’s a matter of some urgency for the FDA to help sort out what is admittedly a complicated and challenging scenario,” said Dr. Ofer Levy of Boston Children’s Hospital.

The government says all three U.S. vaccines continue to offer strong protection against hospitalization and death from COVID-19, and that the priority is getting first shots to the 66 million eligible but unvaccinated Americans who are most at risk. But with the spread of the extra-contagious delta variant and signs of waning immunity against milder infections, the nation is moving toward a broader booster campaign.

Last month Pfizer boosters started being offered to seniors and younger adults at high risk from COVID-19 because of poor health, jobs or living conditions — at least six months after their initial vaccination. Thursday, the FDA advisory panel recommended the same approach for half-dose Moderna boosters.

But J&J’s vaccine has consistently shown lower effectiveness levels across a series of studies — and the FDA panel ultimately settled on another shot for any recipient 18 or older at least two months after their first vaccination.

“This is really — with the second dose — bringing it, I think, on par with those other vaccines in terms of effectiveness,” said Dr. Archana Chatterjee of Rosalind Franklin University.

The FDA will use its advisers’ recommendations to decide whether to authorize boosters for both J&J and Moderna. Next, the Centers for Disease Control and Prevention would rule on who should roll up their sleeves.

The vast majority of the 188 million Americans who are fully vaccinated against COVID-19 have received the Pfizer or Moderna options, while J&J recipients account for only about 15 million.

J&J’s vaccine is made with a different technology and on Friday, the company pitched its booster as a way to strengthen a robust vaccine that they said has retained its protective power over eight months. But FDA scientists pointedly challenged that assertion.

“There are data that suggest the effectiveness of this vaccine is actually less robust than the company’s presentation here,” said Dr. Peter Marks, FDA’s top vaccines official. “And that is a finding of concern particularly because that’s been seen in minority communities potentially and others.”

As for its booster, J&J presented results from a large study that found giving a second dose just two months after the first bumped protection against symptomatic COVID-19 to 94% from 70% in U.S. recipients. Giving that booster six months later instead prompted an even bigger jump in virus-fighting antibodies.

But in their own review, FDA scientists noted only a tiny portion of cases involved the delta variant, by far the dominant strain in the U.S. And while FDA’s reviewers found no new safety concerns about a second J&J dose, they noted other shortcomings. J&J followed booster recipients for little more than a month, making it hard to draw conclusions about the durability of protection. Also, FDA scientists stressed they hadn’t had time to independently confirm J&J’s data, which were submitted shortly before the meeting. That’s highly unusual and drew serious concern from the advisory panel.

The J&J vaccine was highly anticipated for its one-and-done formulation. But its rollout earlier this year was hurt by a series of troubles including manufacturing problems and some rare but serious side effects including a blood clot disorder and a neurological reaction called Guillain-Barre syndrome. In both cases, regulators decided the shot’s benefits outweighed those risks.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

United States News

High gas prices are posted at a full service gas station in Beverly Hills, Calif., Nov. 7, 2021. Oi...
Associated Press

A key inflation gauge rose 5.8% in 2021, most in 39 years

WASHINGTON (AP) — A measure of prices that is closely tracked by the Federal Reserve rose 5.8% last year, the sharpest increase since 1982, as brisk consumer spending collided with snarled supply chains to raise the costs of food, furniture, appliances and other goods. The report Friday from the Commerce Department also said that consumer […]
18 hours ago
This cover image released by Pantheon shows "Maus" a graphic novel by Art Spiegelman. A Tennessee s...
Associated Press

Sales soar for ‘Maus’ after its banning in Tennessee

NEW YORK (AP) — Just days after the banning of “Maus” by a Tennessee school district made national news, two editions of Art Spiegelman’s Pulitzer Prize winning graphic novel about the Holocaust have reached the top 20 on Amazon.com and are in limited supply. “Maus” was No. 12 on Amazon as of early Friday evening, […]
18 hours ago
FILE - "We accept Bitcoin" is announced at a barber shop in Santa Tecla, El Salvador, Sept. 4, 2021...
Associated Press

IMF urges El Salvador to scale back its Bitcoin push

NEW YORK (AP) — The International Monetary Fund said Friday that El Salvador should dissolve the $150 million trust fund it created when it made the cryptocurrency Bitcoin legal tender and return any of those unused funds to its treasury. The recommendation was part of the international lender’s report on El Salvador’s economy and went […]
18 hours ago
FILE - Esau Sinnok of Shishmaref, Alaska, speaks at a news conference after the Alaska Supreme Cour...
Associated Press

Alaska court rules against youths in climate change lawsuit

ANCHORAGE, Alaska (AP) — The Alaska Supreme Court on Friday upheld the dismissal of a lawsuit filed by 16 young Alaskans who claimed long-term effects of climate change will devastate Alaska and interfere with their individual constitutional rights. The lawsuit against the state of Alaska claimed the state’s legislative and executive branches had not taken […]
18 hours ago
Associated Press

Wisconsin Supreme Court keeps ballot boxes in place for now

MADISON, Wis. (AP) — A divided Wisconsin Supreme Court on Friday allowed absentee ballot boxes to remain in place for the Feb. 15 statewide spring primary election for local offices, but said it will decide later about their legality going forward. The court agreed to take the case, as requested by a conservative group, but […]
18 hours ago
This image shows a scene from "Nanny" by Nikyatu Jusu, an official selection of the U.S. Dramatic C...
Associated Press

‘Nanny,’ ‘Exiles,’ ‘Navalny’ among top Sundance winners

A drama about an undocumented nanny in New York City, a documentary about three exiled dissidents from Tiananmen Square and another doc about Russian opposition leader Alexei Navalny won top prizes at the Sundance Film Festival. Winners were announced Friday evening in a virtual ceremony. “Nanny,” from writer-director Nikyatu Jusu and starring Anna Diop and […]
18 hours ago

Sponsored Articles

...
Day & Night Air Conditioning, Heating and Plumbing

HVAC upkeep in Arizona saves money, keeps families prepared in the long run

Does your air conditioner make weird noises or a burning smell when it starts? If so, you may be due for an AC unit replacement.
...
Arizona State University

This is the best year to get your MBA

Getting a master’s degree is a major commitment of time, energy, and money, so returning to school — even if you’re thinking about a part-time program that allows you to keep working — is one of the biggest decisions of your career.
...
Arizona State University

Gain insights on next year’s trends at 58th Annual Economic Forecast Luncheon

Employment is recovering from the severe contraction induced by the pandemic, but it is still way below levels at the start of 2020. Can it fully recover in the coming year?
FDA panel endorses booster shot for J&J COVID-19 vaccine